Get In Touch

Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants below 5 years of age, with peak age group of 2 to 3 years. According to America Cancer Society, neuroblastoma accounts for over 7% of the total cancer cases in age group of 0 to 14 years of age. Statistics also suggest that the cancer equally affects both sexes across the globe. The cancer is rare and American Society of Cancer estimates over 700 cases in 2014 in the U.S. In more than 90% of the cases neuroblastoma is diagnosed before the age of 5. In rare cases, the cancer can be detected in ultrasound before birth. It also found that some forms of neuroblastoma get cured on their own, while others may require multiple treatments. 

Common symptoms of abdominal neuroblastoma include abdominal pain, swelling in legs and altered bowel habits. Neuroblastoma in chest causes symptoms such as wheezing, chest pain, drooping eyelids, and unequal pupils. In majority if the cases, the cancer have already metastasized until it has diagnosed. Most common metastatic sites include bone marrow, skin, liver and bones. Less common symptoms include fever, shortness of breath, high blood pressure, watery diarrhea and uncontrolled eye movement. Scientists suggest that neuroblastoma causes as a result of genetic mutations; however the exact cause of the genetic mutation leading to neuroblastoma is not clear. Further, only about 2% patients have a history of neuroblastoma, and siblings having history of neuroblastoma imply 10 times more chances of being diagnosed with neuroblastoma. Five year survival rate is the percentage of patients living at least 5 years after diagnosis of the cancer. In intermediate risk patients the 5 year survival rate is over 90%, however in high risk patient the rate is 40% to 50%. 

The cancer is diagnosed based on evidence of elevated level of urinary catecholamines and ultrasound or magnetic resonance imaging (MRI) scans. Biopsies are performed to confirm the diagnosis. Localized forms of neuroblastoma are generally treated by surgical removal of tumor.

Various therapeutics have been adopted to treat metastatic neuroblastoma, these include chemotherapy, immunotherapy, and targeted drug therapy. Drugs such as topotecan, irinotecan, and temozolomide, are being studied for application in neuroblastoma. It has also been found that isotretinoin reduces the risk of reoccurrence of the cancer after treatment. Xalkori (crizotinib) by Pfizer has shown promising results in treating neuroblastoma in infants. The drug targets mutations of the ALK gene which lead to development of neuroblastoma. Other drugs approved for treatment of neuroblastoma include Adriamycin PFS (Doxorubicin Hydrochloride), Clafen (Cyclophosphamide), Vincasar PFS (Vincristine Sulfate). Various biopharmaceutical companies and research institutes are conducting research for discovery of better treatment options. A research article published in Journal of Clinical Oncology suggests that black and native American neuroblastoma patients have a higher prevalence of high risk disease. Considering restricted prevalence the global market for neuroblastoma is expected to remain small.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Neuroblastoma Treatment Market

Pre Book